Open house drug discount agreements Formoterol and Fluticason, ATC R03AK11
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Fluticason, ATC R03AK11
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No indication of expected volume or historical spend; revenue may be low or zero.
Open-house agreements automatically terminate if a competitive discount contract (nationwide or regional) for the same...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Non-exclusive discount agreements for pharmaceutical products containing Formoterol and Fluticason (ATC R03AK11)
- Contracting with all eligible pharmaceutical companies on identical terms
Show full summary
This is an open-house model (not a public procurement procedure) by AOK Bayern for non-exclusive drug discount agreements on Formoterol and Fluticason (ATC R03AK11). All eligible pharmaceutical companies can join by submitting a signed contract, annex, and declaration of reliability. Contracts run from May 2025 to April 2027, with enrollment possible until March 5, 2027. No estimated value, award criteria, or competitive selection is involved.
Risks
No indication of expected volume or historical spend; revenue may be low or zero.
Open-house agreements automatically terminate if a competitive discount contract (nationwide or regional) for the same...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company
Certifications
- Documents in German or with certified translation
Administrative
- Submit signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house drug discount agreements Formoterol and Fluticason, ATC R03AK11
Non-exclusive discount agreements for pharmaceutical products containing Formoterol and Fluticason. All eligible pharma companies can join. Contract period: 2025-05-01 to 2027-04-30. Latest enrolment: 2027-03-05.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Formoterol und Fluticason, ATC R03AK11
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 18 Mar 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 176919-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No indication of expected volume or historical spend; revenue may be low or zero.
Open-house agreements automatically terminate if a competitive discount contract (nationwide or regional) for the same...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications